Victrex plc (LON:VCT)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 548.38M |
| Revenue (ttm) | 292.70M |
| Net Income (ttm) | 27.80M |
| Shares Out | 87.05M |
| EPS (ttm) | 0.32 |
| PE Ratio | 19.81 |
| Forward PE | 15.28 |
| Dividend | 0.60 (9.45%) |
| Ex-Dividend Date | Jan 29, 2026 |
| Volume | 220,494 |
| Average Volume | 238,182 |
| Open | 630.00 |
| Previous Close | 638.00 |
| Day's Range | 625.00 - 646.00 |
| 52-Week Range | 581.00 - 1,048.00 |
| Beta | 0.65 |
| RSI | 34.29 |
| Earnings Date | May 11, 2026 |
About Victrex
Victrex plc, through its subsidiaries, engages in the manufacture and sale of polymer solutions worldwide. The company operates through two segments, Sustainable Solutions and Medical. It develops PEEK and PAEK based polymer solutions, and semi-finished and finished parts. The company also provides specialist solutions for medical device manufacturers; and sells thermoplastic polymers; sustainable solutions for energy and industrial, VAR, aerospace, automotive, and electronics markets, as well as engages in trading activities. It serves automot... [Read more]
Financial Performance
In fiscal year 2025, Victrex's revenue was 292.70 million, an increase of 0.58% compared to the previous year's 291.00 million. Earnings were 27.80 million, an increase of 61.63%.
Financial StatementsNews
UK Stock Market News: Tandem, Victrex, Berkeley Energia
Tandem spins up revenue growth, Victrex notes weak start to year, eyes better H2, billion dollar claim lodged by Berkeley Energia vs Spain
Invibio, Part of Victrex plc, Announces New Collaboration With Paragon Medical to Support Scale Up of PEEK Based Trauma Devices
LANCASTER, England--(BUSINESS WIRE)--Invibio establishes composite trauma manufacturing capacity in China, by collaborating with Paragon Medical.
Victrex Has Growth and Value
Victrex PLC ( LSE:VCT , Financial) is a British specialty chemicals company that is a world leader in high-performance polymer solutions.